Monday, March 2, 2020 Daily Archives

Fujifilm kicks off gene therapy expansion in Texas

by

CDMO Fujifilm Diosynth Biotechnologies has begun constructing a $35 million expansion at its College Station, Texas site, intended to feed the demand for gene therapy services. Having announced the expansion in November, contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has begun adding cell culture and high throughput manufacturing suites at its College Station, Texas plant, to support the growing demand for of gene therapy production. The investment represents $35 million of the JPY 13 billion ($120 million) injection…

March 2, 2020

Coherus eyes ophthalmology biosimilars prize

by

In-licensing a Lucentis biosimilar goes “hand-in-hand†with its internally developed Eylea biosimilar, says Coherus BioSciences. Californian biosimilar developer Coherus acquired the US commercial rights in November to commercialize a version of Lucentis (ranibizumab) from Bioeq, a joint venture between Polpharma Group and Strüngmann Group. The ophthalmic monoclonal antibody pulled in US sales of CHF 1.83 billion ($1.9 billion) for Roche/Genentech in 2019. Concurrently, Coherus has a biosimilar candidate looking to take on Regeneron’s Eylea (aflibercept) in the form of CHS-2020.…

March 2, 2020

Ori biotech adds traceability to cell therapy platform in deal with TrakCel

by

Ori Biotech has partnered with software firm TrakCel to add supply chain monitoring technology to its cell and gene therapy manufacturing system. The non-exclusive deal – financial terms of which were not disclosed – will allow cell and gene therapy developers and contract development and manufacturing organizations (CDMOs) that use the Ori platform to monitor manufacturing processes in real-time using Trakcel’s technologies. The firms plan to develop “suitable points of integration in order for a shared data platform to be…

March 2, 2020